Mereo Biopharma Group Plc ADR [MREO] stock prices are up 3.29% to $4.08 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MREO shares have gain 5.15% over the last week, with a monthly amount glided 16.57%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Mereo Biopharma Group Plc ADR [NASDAQ: MREO] stock has seen the most recent analyst activity on June 13, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $8. On August 12, 2022, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $4 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $10 on May 05, 2021. Needham initiated its recommendation with a Buy and recommended $10 as its price target on April 05, 2021.
The stock price of Mereo Biopharma Group Plc ADR [MREO] has been fluctuating between $1.07 and $4.50 over the past year. Currently, Wall Street analysts expect the stock to reach $6.75 within the next 12 months. Mereo Biopharma Group Plc ADR [NASDAQ: MREO] shares were valued at $4.08 at the most recent close of the market. An investor can expect a potential return of 65.44% based on the average MREO price forecast.
Analyzing the MREO fundamentals
Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at -3.87%, Pretax Profit Margin comes in at -3.7%, and Net Profit Margin reading is -3.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -0.73 and Total Capital is -0.83. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.89 points at the first support level, and at 3.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.27, and for the 2nd resistance point, it is at 4.45.
Ratios To Look Out For
It’s worth pointing out that Mereo Biopharma Group Plc ADR [NASDAQ:MREO]’s Current Ratio is 4.86. As well, the Quick Ratio is 4.86, while the Cash Ratio is 4.42. Considering the valuation of this stock, the price to sales ratio is 65.11, the price to book ratio is 13.36.
Transactions by insiders
Recent insider trading involved Scots-Knight Denise, Chief Executive Officer, that happened on Jun 26 ’24 when 92273.0 shares were sold. General Counsel, Sermon Charles completed a deal on Jun 26 ’24 to sell 32187.0 shares. Meanwhile, Chief Financial Officer Fox Christine Ann sold 29439.0 shares on Jun 26 ’24.
